mazdutide vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
mazdutide
Marketed by Innovent Biologics under a licence from Eli Lilly
NCT05607680 · Phase 3 · completed
GLORY-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in China. It assigned 610 adults with obesity or overweight to mazdutide 4 mg, mazdutide 6 mg or placebo once weekly. The two primary endpoints at week 32 were the percent change in body weight and the proportion of participants who lost at least 5% of their body weight. Both doses were significantly better than placebo on both endpoints (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine.
Next expected readout: December 2026 · NCT06884293 (registry estimate)
Reported efficacy
Co-primary: percent change in body weight from baseline to week 32, and proportion of participants with at least 5% body-weight reduction at week 32: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met. (met)
Result source: NCT05607680
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06077864 · Phase 3 · completed
The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.
Next expected readout: December 2026 · NCT07768813 (registry estimate)
Reported efficacy
Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). (met)
Result source: NCT06066515
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | mazdutide | survodutide |
|---|---|---|
| Body weight, % change | -7.3% vs -0.8%−6.5 vs placeboNCT061248077 other results
| -14.9% vs -2.8%−12.1 vs placeboNCT046673774 other results
|
| Weight loss of 5% or more | 74.8% vs 26.0%+48.8 vs placeboNCT061248075 other results
| 82.8% vs 25.9%+56.9 vs placeboNCT046673773 other results
|
| Weight loss of 10% or more | 57.9% vs 13.8%+44.1 vs placeboNCT061248075 other results
| 68.8% vs 11.1%+57.7 vs placeboNCT046673773 other results
|
| Waist circumference, change (cm) | —Not posted · NCT05607680 | -16.0 vs -4.0−12 vs placeboNCT046673773 other results
|
Body weight, % change
- mazdutide
- -7.3% vs -0.8%−6.5 vs placeboNCT06124807
7 other results
- -18.1% vs -0.8% NCT06124807
- -15.6% vs -0.8% NCT06124807
- -10.5% vs -0.0% NCT06124807
- -22.3% vs -0.0% NCT06124807
- -19.2% vs -0.0% NCT06124807
- -12.6% vs 0.5% NCT05607680
- -10.1% vs 0.5% NCT05607680
- survodutide
- -14.9% vs -2.8%−12.1 vs placeboNCT04667377
4 other results
- -13.2% vs -2.8% NCT04667377
- -12.5% vs -2.8% NCT04667377
- -6.2% vs -2.8% NCT04667377
- -16.6% vs -3.2% NCT06066515
Weight loss of 5% or more
- mazdutide
- 74.8% vs 26.0%+48.8 vs placeboNCT06124807
5 other results
- 67.6% vs 24.0% NCT06124807
- 91.9% vs 26.0% NCT06124807
- 92.2% vs 24.0% NCT06124807
- 95.9% vs 26.0% NCT06124807
- 96.1% vs 24.0% NCT06124807
- survodutide
- 82.8% vs 25.9%+56.9 vs placeboNCT04667377
3 other results
- 82% vs 25.9% NCT04667377
- 81% vs 25.9% NCT04667377
- 60.7% vs 25.9% NCT04667377
Weight loss of 10% or more
- mazdutide
- 57.9% vs 13.8%+44.1 vs placeboNCT06124807
5 other results
- 45.4% vs 8.7% NCT06124807
- 80.7% vs 13.8% NCT06124807
- 77.1% vs 8.7% NCT06124807
- 84.0% vs 13.8% NCT06124807
- 86.0% vs 8.7% NCT06124807
- survodutide
- 68.8% vs 11.1%+57.7 vs placeboNCT04667377
3 other results
- 65.6% vs 11.1% NCT04667377
- 65.5% vs 11.1% NCT04667377
- 33.9% vs 11.1% NCT04667377
Waist circumference, change (cm)
- mazdutide
- —Not posted · NCT05607680
- survodutide
- -16.0 vs -4.0−12 vs placeboNCT04667377
3 other results
- -15.0 vs -4.0 NCT04667377
- -15.0 vs -4.0 NCT04667377
- -8.3 vs -4.0 NCT04667377
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. mazdutide: 5 of 5 rows · survodutide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | mazdutide | survodutide Rows use multiple source trials |
|---|---|---|
| Weight absolute change · kg | -11.15 vs -0.15 placebo kg @ 48wk3/6 mga,b,c,d NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more doses-23.9 vs -0.15 placebo kg @ 48wk16 mg NCT06124807 · Phase 2 · registry result, not featured evidence -19.7 vs -0.15 placebo kg @ 48wk10 mg NCT06124807 · Phase 2 · registry result, not featured evidence | -18.47 vs -2.68 placebo kg @ 46wk4.8 mga,b,c,d NCT04667377 · Phase 2 · registry result, not featured evidence show 3 more doses-15.64 vs -2.68 placebo kg @ 46wk3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence -14.75 vs -2.68 placebo kg @ 46wk2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence -7.21 vs -2.68 placebo kg @ 46wk0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 12.5%3/6 mge NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results33.3%16 mg NCT06124807 · Phase 2 · registry result, not featured evidence 22.9%10 mg NCT06124807 · Phase 2 · registry result, not featured evidence | —4.8 mge NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results28.6%4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 23.4%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 23.1%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 29.5%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%3/6 mge NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results9.8%16 mg NCT06124807 · Phase 2 · registry result, not featured evidence 4.2%10 mg NCT06124807 · Phase 2 · registry result, not featured evidence | —4.8 mge NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results23.4%4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 18.2%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 14.1%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 16.7%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.1%3/6 mge NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results3.9%16 mg NCT06124807 · Phase 2 · registry result, not featured evidence 2.1%10 mg NCT06124807 · Phase 2 · registry result, not featured evidence | 7.4%4.8 mge NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results—4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence 5.6%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 3.3%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 2.2%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 3/6 mge nausea 43.8% (placebo 25.5%) diarrhoea 28.1% (placebo 12.8%) constipation 21.9% (placebo 10.6%) NCT06124807 · Phase 2 · registry result, not featured evidence show 2 more results16 mg nausea 66.7% (placebo 25.5%) vomiting 47.1% (placebo 2.1%) constipation 37.3% (placebo 10.6%) NCT06124807 · Phase 2 · registry result, not featured evidence 10 mg nausea 46.8% (placebo 25.5%) constipation 29.8% (placebo 10.6%) diarrhoea 25.5% (placebo 12.8%) NCT06124807 · Phase 2 · registry result, not featured evidence | 4.8 mge nausea 59.3% (placebo 19.5%) constipation 24.1% (placebo 5.2%) vomiting 24.1% (placebo 5.2%) NCT04667377 · Phase 2 · registry result, not featured evidence show 3 more results3.6 mg nausea 63.4% (placebo 19.5%) vomiting 39.4% (placebo 5.2%) constipation 31% (placebo 5.2%) NCT04667377 · Phase 2 · registry result, not featured evidence 2.4 mg nausea 65.2% (placebo 19.5%) vomiting 30.4% (placebo 5.2%) diarrhoea 22.8% (placebo 10.4%) NCT04667377 · Phase 2 · registry result, not featured evidence 0.6 mg nausea 39.1% (placebo 19.5%) diarrhoea 23.9% (placebo 10.4%) covid-19 19.6% (placebo 22.1%) NCT04667377 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 46 weeks versus 48 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
mazdutide
show 5 more results
show 11 more results
show 11 more results
show 11 more results
survodutide
show 3 more results
show 3 more results
show 3 more results
show 3 more results
Type 2 Diabetes
Shared mechanism: GLP-1/glucagon receptor (dual) · full Type 2 Diabetes pipeline
mazdutide
Marketed by Innovent Biologics under a licence from Eli Lilly
NCT05606913 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial of 731 people with type 2 diabetes. Both mazdutide doses lowered blood sugar (HbA1c) significantly more than the comparator drug dulaglutide, a difference that reached statistical significance.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2027 · NCT07713992 (registry estimate)
Reported efficacy
HbA1c change from baseline at week 28 (Baseline, 28 weeks): HbA1c change from baseline at Week 28: -1.61 percentage points (mazdutide 4mg) and -1.66 percentage points (mazdutide 6mg) vs -1.36 percentage points (dulaglutide 1.5mg); superiority P<.01 for both doses. (met)
Result source: NCT05606913
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06066528 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in adults with obesity and type 2 diabetes (755 enrolled on the registry, 752 randomized in the publication), with co-primary clinical weight-loss endpoints at Week 76. The published primary analysis (treatment-regimen estimand) shows both co-primary endpoints met: mean weight change of -9.8% with 6.0 mg and -8.2% with 3.6 mg versus -3.9% with placebo, and 64.5% and 57.6% versus 35.1% of participants reached at least 5% weight reduction (P<0.001 for all comparisons).
Next expected readout: January 2028 · NCT07754461 (registry estimate)
Reported efficacy
Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo). (met)
Result source: NCT06066528
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | mazdutide | survodutide |
|---|---|---|
| HbA1c, change | -2.1% vs -0.1%a−2 vs placeboNCT056283113 other results
| -1.7% vs -0.2%−1.4 vs placeboNCT041539295 other results
|
| Body weight, change (kg) | —Not posted · NCT05628311 | -6.9 vs -1.3−5.6 vs placeboNCT041539295 other results
|
| HbA1c below 7% | —Not posted · NCT05628311 | —Not posted · NCT06066528 |
| Fasting plasma glucose, change | —Not posted · NCT05628311 | —Not posted · NCT06066528 |
| 3-point MACE (% with event) | —Not posted · NCT05628311 | —Not posted · NCT06066528 |
HbA1c, change
- mazdutide
- -2.1% vs -0.1%a−2 vs placeboNCT05628311
3 other results
- -1.6% vs -0.1% NCT05628311
- -1.7% vs -1.4% NCT05606913
- -1.6% vs -1.4% NCT05606913
- survodutide
- -1.7% vs -0.2%−1.4 vs placeboNCT04153929
5 other results
- -1.8% vs -0.2% NCT04153929
- -1.8% vs -0.2% NCT04153929
- -1.7% vs -0.2% NCT04153929
- -1.4% vs -0.2% NCT04153929
- -0.9% vs -0.2% NCT04153929
Body weight, change (kg)
- mazdutide
- —Not posted · NCT05628311
- survodutide
- -6.9 vs -1.3−5.6 vs placeboNCT04153929
5 other results
- -6.3 vs -1.3 NCT04153929
- -8.9 vs -1.3 NCT04153929
- -6.8 vs -1.3 NCT04153929
- -4.4 vs -1.3 NCT04153929
- -1.9 vs -1.3 NCT04153929
HbA1c below 7%
- mazdutide
- —Not posted · NCT05628311
- survodutide
- —Not posted · NCT06066528
Fasting plasma glucose, change
- mazdutide
- —Not posted · NCT05628311
- survodutide
- —Not posted · NCT06066528
3-point MACE (% with event)
- mazdutide
- —Not posted · NCT05628311
- survodutide
- —Not posted · NCT06066528
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. mazdutide: 0 of 4 rows · survodutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | mazdutide | survodutide |
|---|---|---|
| Dropout rate | — | 34%2.7 mga NCT04153929 · Phase 2 · registry result, not featured evidence show 5 more results26%1.8 mg twice weekly (3.6 mg) NCT04153929 · Phase 2 · registry result, not featured evidence 30.8%1.8 mg NCT04153929 · Phase 2 · registry result, not featured evidence 11.8%1.2 mg twice weekly (2.4 mg) NCT04153929 · Phase 2 · registry result, not featured evidence 10%0.9 mg NCT04153929 · Phase 2 · registry result, not featured evidence 18%0.3 mg NCT04153929 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 30%2.7 mga NCT04153929 · Phase 2 · registry result, not featured evidence show 5 more results16%1.8 mg twice weekly (3.6 mg) NCT04153929 · Phase 2 · registry result, not featured evidence 21.2%1.8 mg NCT04153929 · Phase 2 · registry result, not featured evidence 7.8%1.2 mg twice weekly (2.4 mg) NCT04153929 · Phase 2 · registry result, not featured evidence 10%0.9 mg NCT04153929 · Phase 2 · registry result, not featured evidence 10%0.3 mg NCT04153929 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 4%2.7 mga NCT04153929 · Phase 2 · registry result, not featured evidence show 5 more results0%1.8 mg twice weekly (3.6 mg) NCT04153929 · Phase 2 · registry result, not featured evidence 5.8%1.8 mg NCT04153929 · Phase 2 · registry result, not featured evidence 2%1.2 mg twice weekly (2.4 mg) NCT04153929 · Phase 2 · registry result, not featured evidence 8%0.9 mg NCT04153929 · Phase 2 · registry result, not featured evidence 2%0.3 mg NCT04153929 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | 2.7 mga nausea 46% (placebo 8.5%) vomiting 26% (placebo 5.1%) decreased appetite 22% (placebo 3.4%) NCT04153929 · Phase 2 · registry result, not featured evidence show 5 more results1.8 mg twice weekly (3.6 mg) nausea 46.9% (placebo 8.5%) decreased appetite 30.6% (placebo 3.4%) diarrhoea 22.4% (placebo 11.9%) NCT04153929 · Phase 2 · registry result, not featured evidence 1.8 mg nausea 48.1% (placebo 8.5%) vomiting 23.1% (placebo 5.1%) diarrhoea 17.3% (placebo 11.9%) NCT04153929 · Phase 2 · registry result, not featured evidence 1.2 mg twice weekly (2.4 mg) nausea 27.5% (placebo 8.5%) decreased appetite 17.6% (placebo 3.4%) constipation 15.7% (placebo 0%) NCT04153929 · Phase 2 · registry result, not featured evidence 0.9 mg nausea 28% (placebo 8.5%) vomiting 18% (placebo 5.1%) diarrhoea 16% (placebo 11.9%) NCT04153929 · Phase 2 · registry result, not featured evidence 0.3 mg diarrhoea 24% (placebo 11.9%) nausea 20% (placebo 8.5%) vomiting 14% (placebo 5.1%) NCT04153929 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
survodutide
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mazdutide's landscape · survodutide's landscape